Many oncogene activating mutations and cytogenetic abnormalities in AML, such as core-binding factor (CBF), retinoic acid receptor-α (RAR-α), FLT3, RAS, p53, WNT, nucleophosmin (NPM1), and CEPBAdouble, are associated with high-risk clinical characteristics and adverse prognosis [3–5]. The gene discussed is NPM1; the disease is acute myeloid leukemia.